STING Agonists & Antagonists – Target Pipeline List 04/2020
STING Agonists & Antagonists – Target Pipeline List 04/2020
Target: STING; STimulator of INterferon Genes; MITA; MPYS
This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases
Stimulator of interferon genes (STING) is an adaptor protein that induces the secretion of type I interferons and proinflammatory cytokines and is triggered by cytosolic DNA of pathogen and host origins. Given that STING is a mediator in the immune system, pharmacological modulation of STING has shown viable therapeutic effects for pathogen infection, cancer, and inflammatory diseases. In the past decade, the substantial development in this field has encouraged the discovery of STING modulators.
STING has emerged as an innate immune pathway capable of inducing anti-tumor immune activity by stimulating antigen presenting cells and type I interferon production, leading to T-cell priming and activation. In preclinical models, STING agonists have been shown to induce tumor regressions and generate immunological memory.
STING is also known to play a role in activating the innate immune system in auto-inflammatory diseases. Thus, STING antagonists offer tremendous potential for new treatments.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.